Literature DB >> 32740893

The natural history of weight and swallowing outcomes in oropharyngeal cancer patients following radiation or concurrent chemoradiation therapy.

Nedeljko Jovanovic1, Colleen Dreyer2, Sarah Hawkins2, Kendra Thouless2, David Palma2,3, Philip C Doyle1,3,4,5, Julie A Theurer6,7,8,9.   

Abstract

PURPOSE: Patients treated for oropharyngeal cancer (OPC) are at increased risk for functional decline due to cancer-related impairments and treatment toxicities, often leading to recommendations for enteral nutritional support. This study investigated the natural history of weight and swallowing outcomes in patients with and without feeding tube (FT) placement.
METHODS: Data were collected from electronic medical records of OPC patients treated with (chemo)radiotherapy at a single regional cancer center between January 2013 and December 2015. Weight measurements, Functional Oral Intake Scale (FOIS) scores, Performance Status Scale for Head and Neck Cancer (PSS-HN) normalcy of diet scores, and M.D. Anderson Dysphagia Inventory (MDADI) composite scores were gathered at baseline and at 3-, 6-, and 12-months post-treatment. Patients were grouped based on FT placement and change over time was assessed using linear mixed effects analysis.
RESULTS: Of 122 eligible patients, 38 (31.1%) received a FT (FT group). Compared with baseline, weight decreased significantly at 3 and 6 months in both groups and at 12 months for patients without a FT (NFT group). Swallowing-related quality of life (QoL) decreased significantly at 3 and 6 months only in the NFT group.
CONCLUSION: OPC patients experience clinically relevant decreases in weight and swallowing-related QoL in the first-year post-treatment irrespective of FT placement. These findings will contribute to improved patient monitoring and communication within the clinical setting which may ultimately lead to better outcomes for those with OPC.

Entities:  

Keywords:  Chemoradiotherapy; Dysphagia; Feeding tube; Oropharyngeal cancer; Quality of life

Mesh:

Year:  2020        PMID: 32740893     DOI: 10.1007/s00520-020-05628-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  43 in total

1.  Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.

Authors:  Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 2.  Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

Authors:  Jacques Bernier; Jay S Cooper
Journal:  Oncologist       Date:  2005-03

Review 3.  The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review.

Authors:  Stephanie M Shaw; Heather Flowers; Brian O'Sullivan; Andrew Hope; Louis W C Liu; Rosemary Martino
Journal:  Dysphagia       Date:  2015-03-04       Impact factor: 3.438

4.  Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.

Authors:  E E Vokes; M S Kies; D J Haraf; K Stenson; M List; R Humerickhouse; M E Dolan; H Pelzer; L Sulzen; M E Witt; Y C Hsieh; B B Mittal; R R Weichselbaum
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.

Authors:  Laura B Moroney; Jennifer Helios; Elizabeth C Ward; Jane Crombie; Leesa F Wockner; Clare L Burns; Ann-Louise Spurgin; Claire Blake; Lizbeth Kenny; Brett G M Hughes
Journal:  Oral Oncol       Date:  2016-11-25       Impact factor: 5.337

6.  Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.

Authors:  Ryan P Goepfert; Jan S Lewin; Martha P Barrow; C David Fuller; Stephen Y Lai; Juhee Song; Brian P Hobbs; G Brandon Gunn; Beth M Beadle; David I Rosenthal; Adam S Garden; Merrill S Kies; Vali A Papadimitrakopoulou; David L Schwartz; Katherine A Hutcheson
Journal:  Laryngoscope       Date:  2016-07-21       Impact factor: 3.325

7.  Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.

Authors:  J L Aguilar-Ponce; M Granados-García; J C Cruz López; F Maldonado-Magos; M A Alvarez-Avitia; O Arrieta; I González-Ramírez; G Lara-Cruz; I Martinez-Juárez; R Medina-Santillan; C Castillo-Hernández; J De la Garza-Salazar
Journal:  Oral Oncol       Date:  2012-10-06       Impact factor: 5.337

8.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

9.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Authors:  David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

10.  A comprehensive review of head and neck cancer rehabilitation: physical therapy perspectives.

Authors:  Karthikeyan Guru; Udaya Kumar Manoor; Sanjay Sudhakar Supe
Journal:  Indian J Palliat Care       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.